House OKs PDUFA bill, sans DTC restrictions

Share this article:
The House has approved legislation that would reauthorize PDUFA and strengthen the FDA’s hand, allowing it to require post-market drug safety studies and fine companies as much as $250,000 for airing false and misleading ads.
The vote was 403-16.
Measures imposing a moratorium on advertising of new drugs and requiring preapproval of ads were stripped from the bill in committee last month.
The legislation must now be consolidated with its Senate counterpart. Barring any hitches (a contentious Senate bill on generic biologics could, if thrown into the mix, present a stumbling block) the bill could reach the President’s desk in the next two weeks.
“Now the devil’s in the details,” said John Kamp, executive director of the Coalition for Healthcare Communications. “The [Risk Evaluation and Mitigation Strategies] program giving the FDA more power to ensure drug safety is a victory for everyone. How the FDA exercises that power is going to make all the difference.”

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?